Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...
Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...
Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival ...
A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.
Forbion has touted its “landmark” 2.3 billion euro ($2.6 billion) fundraise across two funds as a new record for the European ...
Abbott has been given U.S. clearance for new updates to its CardioMEMS HF System that allow for patient-facing capabilities ...
Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...
Using a short lapidated peptide (SLiP) developed by Mimetic Medicines disrupted a crucial voltage-gated sodium channel ...
Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...
A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...
The FDA has approved a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease. | The FDA has approved a surgically implanted pulmonary heart valve ...
Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results